Inside Therapeutics x Meiwafosis: bringing TAMARA to Japan

A new step in TAMARA’s global expansion

Following growing adoption across Europe, driven by academic labs and biotech companies, with installations at renowned institutions, TAMARA continues its international rollout.  

Since 1968, Meiwafosis has been connecting Japanese universities, research institutions, and companies with the best scientific instruments the world has to offer. Five locations, decades of technical expertise, and a reputation built on genuinely understanding what researchers need: a strong foundation to bring TAMARA to Japan.

Japan: a new chapter begins

Researchers will now have local access to TAMARA, with demos, training, and technical support available directly in Japan. In practice, that means faster support and fewer delays for teams working on RNA-LNPs, liposomes, peptide nanoparticles, or other nanoparticle-based delivery systems, from early screening (200 µL) through preclinical development (up to 30 mL), all within the same system.

Ryushi Fukuda, President & CEO at Meiwafosis, put it well: 

“Our partnership with Inside Therapeutics reflects our long-standing commitment to advancing scientific research in Japan. TAMARA is exactly the kind of innovation we’re proud to introduce to our network, a solution that will help accelerate nanoparticles and RNA-based research across the country.” 

This partnership builds on TAMARA’s growing footprint across Europe, and Japan is a natural next step, a research ecosystem that moves fast and demands tools that can keep up. 

Curious to see TAMARA in action? Reach out to the Meiwafosis team, or get in touch with us directly. 

Let’s shape the future of nanoparticle formulation, together!